吉特替尼联合阿扎胞苷组合在新诊断的 FLT3 突变 AML 中显示出前景。
Gilteritinib Plus Azacitidine Combination Shows Promise in Newly Diagnosed FLT3-Mutated AML.
出版信息
Oncologist. 2021 Feb;26 Suppl 1(Suppl 1):S10. doi: 10.1002/onco.13652. Epub 2020 Dec 24.
Abstract
New data from the phase III LACEWING trial support the safety and feasibility of combining gilteritinib with azacitidine in patients with newly diagnosed ‐mutated acute myeloid leukemia who are not eligible for induction therapy, suggesting an important new treatment approach for these patients.
摘要
III 期 LACEWING 试验的新数据支持 gilteritinib 联合阿扎胞苷用于不适合诱导治疗的新诊断突变型急性髓系白血病患者的安全性和可行性，这为这些患者提供了一种重要的新治疗方法。
相似文献
1
Gilteritinib Plus Azacitidine Combination Shows Promise in Newly Diagnosed FLT3-Mutated AML.吉特替尼联合阿扎胞苷组合在新诊断的 FLT3 突变 AML 中显示出前景。
Oncologist. 2021 Feb;26 Suppl 1(Suppl 1):S10. doi: 10.1002/onco.13652. Epub 2020 Dec 24.
2
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory -Mutated AML.阿扎胞苷、维奈托克和吉特替尼治疗新诊断和复发/难治性 - 突变 AML。
J Clin Oncol. 2024 May 1;42(13):1499-1508. doi: 10.1200/JCO.23.01911. Epub 2024 Jan 26.
3
Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a mutation.吉特替尼用于治疗携带 突变的复发或难治性急性髓系白血病。
Future Oncol. 2021 Jan;17(2):215-227. doi: 10.2217/fon-2020-0700. Epub 2020 Sep 25.
4
The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia.吉特替尼治疗后 FLT3 突变清除和治疗反应对 FLT3 突变阳性复发/难治性急性髓系白血病患者总生存期的影响。
Cancer Med. 2021 Feb;10(3):797-805. doi: 10.1002/cam4.3652. Epub 2020 Dec 19.
5
Triplet therapy with gilteritinib, venetoclax, and azacitidine for relapsed/refractory FLT3 acute myeloid leukemia.吉特替尼、维奈托克和阿扎胞苷三联疗法治疗复发/难治性 FLT3 急性髓系白血病。
Leuk Res. 2024 Oct;145:107564. doi: 10.1016/j.leukres.2024.107564. Epub 2024 Aug 22.
6
Gilteritinib or Chemotherapy for Relapsed or Refractory -Mutated AML.吉特替尼与化疗用于治疗复发/难治性 - 突变型 AML。
N Engl J Med. 2019 Oct 31;381(18):1728-1740. doi: 10.1056/NEJMoa1902688.
7
Gilteritinib induces differentiation in relapsed and refractory -mutated acute myeloid leukemia.吉特替尼诱导复发/难治性突变型急性髓系白血病的分化。
Blood Adv. 2019 May 28;3(10):1581-1585. doi: 10.1182/bloodadvances.2018029496.
8
Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia.吉特替尼治疗复发和/或难治性 FLT3 突变型急性髓系白血病。
Expert Rev Clin Pharmacol. 2019 Sep;12(9):841-849. doi: 10.1080/17512433.2019.1657009. Epub 2019 Aug 27.
9
Gilteritinib in Isolated Breast Relapse of FLT3 Positive Acute Myeloid Leukemia: A Case Report and Review of Literature.吉瑞替尼治疗FLT3阳性急性髓系白血病孤立性乳腺复发：一例报告并文献复习
Acta Haematol. 2022;145(5):566-570. doi: 10.1159/000524878. Epub 2022 May 17.
10
Gilteritinib vs salvage chemotherapy in FLT3-mutated acute myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial.吉瑞替尼与挽救性化疗治疗FLT3突变型急性髓系白血病的比较：基于ADMIRAL试验二次分析的临床结局所需治疗人数
Leuk Lymphoma. 2022 Mar;63(3):762-764. doi: 10.1080/10428194.2021.2001467. Epub 2021 Nov 8.
引用本文的文献
1
Efficacy and safety of second‑generation FLT3 inhibitors in acute myeloid leukemia: A systematic review and meta‑analysis of randomized controlled trials.第二代FLT3抑制剂治疗急性髓系白血病的疗效与安全性：一项随机对照试验的系统评价与Meta分析
Mol Clin Oncol. 2024 Oct 11;21(6):93. doi: 10.3892/mco.2024.2791. eCollection 2024 Dec.
2
Therapeutic Management of Patients with FLT3 + Acute Myeloid Leukemia: Case Reports and Focus on Gilteritinib Monotherapy.FLT3+急性髓系白血病患者的治疗管理：病例报告及对吉列替尼单药治疗的关注
Pharmgenomics Pers Med. 2022 Apr 22;15:393-407. doi: 10.2147/PGPM.S346688. eCollection 2022.
3
Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target Resistance.维奈托克在急性髓系白血病中的应用：分子基础、临床前及临床疗效证据以及靶向耐药的策略
Cancers (Basel). 2021 Nov 9;13(22):5608. doi: 10.3390/cancers13225608.
Zotero 插件